Thompson Investment Management Inc. Has $1.96 Million Stake in Bausch Health Companies Inc. (NYSE:BHC)

Thompson Investment Management Inc. decreased its holdings in Bausch Health Companies Inc. (NYSE:BHC) by 7.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 243,147 shares of the company’s stock after selling 19,615 shares during the quarter. Thompson Investment Management Inc. owned 0.07% of Bausch Health Companies worth $1,960,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. CIBC Asset Management Inc raised its stake in Bausch Health Companies by 0.3% in the 3rd quarter. CIBC Asset Management Inc now owns 374,729 shares of the company’s stock worth $3,060,000 after purchasing an additional 1,082 shares in the last quarter. Tobam increased its holdings in Bausch Health Companies by 10.4% in the 4th quarter. Tobam now owns 15,034 shares of the company’s stock valued at $121,000 after buying an additional 1,422 shares during the period. Northwest & Ethical Investments L.P. increased its holdings in Bausch Health Companies by 13.0% in the 3rd quarter. Northwest & Ethical Investments L.P. now owns 32,384 shares of the company’s stock valued at $264,000 after buying an additional 3,734 shares during the period. Sanders Morris Harris LLC increased its holdings in Bausch Health Companies by 16.0% in the 4th quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company’s stock valued at $234,000 after buying an additional 4,000 shares during the period. Finally, Creative Planning increased its holdings in Bausch Health Companies by 16.9% in the 3rd quarter. Creative Planning now owns 55,351 shares of the company’s stock valued at $452,000 after buying an additional 7,995 shares during the period. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Companies Price Performance

BHC opened at $6.45 on Friday. Bausch Health Companies Inc. has a fifty-two week low of $3.96 and a fifty-two week high of $11.46. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of -13.43, a PEG ratio of 0.34 and a beta of 0.68. The company’s 50 day moving average price is $7.65 and its two-hundred day moving average price is $7.44.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on BHC shares. StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. Evercore ISI raised shares of Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th. Jefferies Financial Group reaffirmed a “hold” rating and set a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a report on Thursday. Finally, Royal Bank of Canada decreased their price target on shares of Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating on the stock in a report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.42.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.